Tech Company Financing Transactions
Vivalyx Funding Round
On 5/1/2024, Vivalyx raised $5.8 million in Seed funding from BVP, TechVision Fonds and private investors.
Transaction Overview
Company Name
Announced On
5/1/2024
Transaction Type
Venture Equity
Amount
$5,800,000
Round
Seed
Investors
BVP (Lead Investor)
TechVision Fonds (Lead Investor)
Proceeds Purpose
The company intends to use the funds to finance the necessary clinical trials to achieve regulatory clearance and to start commercialization.
Company Information
Company Status
Private & Independent
Industry
Manufacturing
Mailing Address
Philipsstr. 8
Aachen, 52068
Germany
Aachen, 52068
Germany
Phone
Website
Email Address
Overview
Vivalyx is dedicated to saving lives of people suffering from organ failure by increasing the vitality and number of donor organs. Vivalyx Omnisol is a patented, blood-free solution for all organs* and all preservation methods* with expected beneficial clinical outcomes for SCS, HMP, HOPE and NMP.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andreas Schumacher
Chief Medical Officer
René Tolba
Chief Scientific Officer
Christian Bleilevens
Chief Technical Officer
Benedict Doorschodt
VP - Regulatory Affairs
Carola Steins-Rang
Browse more venture capital transactions:
Prev: 5/1/2024: Netskrt Systems venture capital transaction
Next: 5/1/2024: Agora venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs